Floatz logo

Sargramostim

Acute Myeloid Leukemia

Sellas Life Sciences Groupprotein_peptidePhase 3Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
59/ 100

Competitive context

373 Active assets in the Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Daunorubicin
Shen yang
Phase 4BB
Idarubicine
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BB
ETOPOSIDE
Memorial Sloan Kettering Cancer Center
Phase 4BB
Cytosin-Arabinosid
M.D. Anderson Cancer Center
Phase 4BB
Decitabine
National Cancer Institute (NCI)
Phase 4BB

View all 50 →

Same molecule, other indications

Sargramostim is also rated in:

cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
chronic myeloid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →